Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
Identifieur interne : 000A19 ( Pmc/Corpus ); précédent : 000A18; suivant : 000A20Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
Auteurs : Ashok K. ShettySource :
- Aging and Disease [ 2152-5250 ] ; 2020.
Abstract
A new study published by the journal Aging & Disease reported that intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with coronavirus disease 2019 (COVID-19) resulted in improved functional outcomes (
Url:
DOI: 10.14336/AD.2020.0301
PubMed: 32257554
PubMed Central: 7069463
Links to Exploration step
PMC:7069463Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia</title><author><name sortKey="Shetty, Ashok K" sort="Shetty, Ashok K" uniqKey="Shetty A" first="Ashok K" last="Shetty">Ashok K. Shetty</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32257554</idno><idno type="pmc">7069463</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069463</idno><idno type="RBID">PMC:7069463</idno><idno type="doi">10.14336/AD.2020.0301</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000A19</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia</title><author><name sortKey="Shetty, Ashok K" sort="Shetty, Ashok K" uniqKey="Shetty A" first="Ashok K" last="Shetty">Ashok K. Shetty</name></author></analytic><series><title level="j">Aging and Disease</title><idno type="eISSN">2152-5250</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>A new study published by the journal Aging & Disease reported that intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with coronavirus disease 2019 (COVID-19) resulted in improved functional outcomes (<italic>Leng et al., Aging Dis, 11:216-228, 2020</italic>). This study demonstrated that intravenous infusion of MSCs is a safe and effective approach for treating patients with COVID-19 pneumonia, including elderly patients displaying severe pneumonia. COVID-19 is a severe acute respiratory illness caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, treating COVID-19 patients, particularly those afflicted with severe pneumonia, is challenging as no specific drugs or vaccines against SARS-CoV-2 are available. Therefore, MSC therapy inhibiting the overactivation of the immune system and promoting endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection found in this study is striking. Additional studies in a larger cohort of patients are needed to validate this therapeutic intervention further, however.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Leng, Z" uniqKey="Leng Z">Z Leng</name></author><author><name sortKey="Zhu, R" uniqKey="Zhu R">R Zhu</name></author><author><name sortKey="Hou, W" uniqKey="Hou W">W Hou</name></author><author><name sortKey="Feng, Y" uniqKey="Feng Y">Y Feng</name></author><author><name sortKey="Yang, Y" uniqKey="Yang Y">Y Yang</name></author><author><name sortKey="Han, Q" uniqKey="Han Q">Q Han</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Munster, Vj" uniqKey="Munster V">VJ Munster</name></author><author><name sortKey="Koopmans, M" uniqKey="Koopmans M">M Koopmans</name></author><author><name sortKey="Van Doremalen, N" uniqKey="Van Doremalen N">N van Doremalen</name></author><author><name sortKey="Van Riel, D" uniqKey="Van Riel D">D van Riel</name></author><author><name sortKey="De Wit, E" uniqKey="De Wit E">E de Wit</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sohrabi, C" uniqKey="Sohrabi C">C Sohrabi</name></author><author><name sortKey="Alsafi, Z" uniqKey="Alsafi Z">Z Alsafi</name></author><author><name sortKey="O Neill, N" uniqKey="O Neill N">N O'Neill</name></author><author><name sortKey="Khan, M" uniqKey="Khan M">M Khan</name></author><author><name sortKey="Kerwan, A" uniqKey="Kerwan A">A Kerwan</name></author><author><name sortKey="Al Jabir, A" uniqKey="Al Jabir A">A Al-Jabir</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Y" uniqKey="Chen Y">Y Chen</name></author><author><name sortKey="Liu, Q" uniqKey="Liu Q">Q Liu</name></author><author><name sortKey="Guo, D" uniqKey="Guo D">D Guo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, R" uniqKey="Lu R">R Lu</name></author><author><name sortKey="Zhao, X" uniqKey="Zhao X">X Zhao</name></author><author><name sortKey="Li, J" uniqKey="Li J">J Li</name></author><author><name sortKey="Niu, P" uniqKey="Niu P">P Niu</name></author><author><name sortKey="Yang, B" uniqKey="Yang B">B Yang</name></author><author><name sortKey="Wu, H" uniqKey="Wu H">H Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhou, P" uniqKey="Zhou P">P Zhou</name></author><author><name sortKey="Yang, X L" uniqKey="Yang X">X-L Yang</name></author><author><name sortKey="Wang, X G" uniqKey="Wang X">X-G Wang</name></author><author><name sortKey="Hu, B" uniqKey="Hu B">B Hu</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author><author><name sortKey="Zhang, W" uniqKey="Zhang W">W Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoffmann, M" uniqKey="Hoffmann M">M Hoffmann</name></author><author><name sortKey="Kleine Weber, H" uniqKey="Kleine Weber H">H Kleine-Weber</name></author><author><name sortKey="Kruger, N" uniqKey="Kruger N">N Krüger</name></author><author><name sortKey="Muller, M" uniqKey="Muller M">M Müller</name></author><author><name sortKey="Drosten, C" uniqKey="Drosten C">C Drosten</name></author><author><name sortKey="Pohlmann, S" uniqKey="Pohlmann S">S Pöhlmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hamming, I" uniqKey="Hamming I">I Hamming</name></author><author><name sortKey="Timens, W" uniqKey="Timens W">W Timens</name></author><author><name sortKey="Bulthuis, Mlc" uniqKey="Bulthuis M">MLC Bulthuis</name></author><author><name sortKey="Lely, At" uniqKey="Lely A">AT Lely</name></author><author><name sortKey="Navis, Gj" uniqKey="Navis G">GJ Navis</name></author><author><name sortKey="Van Goor, H" uniqKey="Van Goor H">H van Goor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fauci, As" uniqKey="Fauci A">AS Fauci</name></author><author><name sortKey="Lane, Hc" uniqKey="Lane H">HC Lane</name></author><author><name sortKey="Redfield, Rr" uniqKey="Redfield R">RR Redfield</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prockop, Dj" uniqKey="Prockop D">DJ Prockop</name></author><author><name sortKey="Oh, Jy" uniqKey="Oh J">JY Oh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prockop, Dj" uniqKey="Prockop D">DJ Prockop</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Connick, P" uniqKey="Connick P">P Connick</name></author><author><name sortKey="Kolappan, M" uniqKey="Kolappan M">M Kolappan</name></author><author><name sortKey="Crawley, C" uniqKey="Crawley C">C Crawley</name></author><author><name sortKey="Webber, Dj" uniqKey="Webber D">DJ Webber</name></author><author><name sortKey="Patani, R" uniqKey="Patani R">R Patani</name></author><author><name sortKey="Michell, Aw" uniqKey="Michell A">AW Michell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wilson, Jg" uniqKey="Wilson J">JG Wilson</name></author><author><name sortKey="Liu, Kd" uniqKey="Liu K">KD Liu</name></author><author><name sortKey="Zhuo, Nj" uniqKey="Zhuo N">NJ Zhuo</name></author><author><name sortKey="Caballero, L" uniqKey="Caballero L">L Caballero</name></author><author><name sortKey="Mcmillan, M" uniqKey="Mcmillan M">M McMillan</name></author><author><name sortKey="Fang, Xh" uniqKey="Fang X">XH Fang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hashmi, S" uniqKey="Hashmi S">S Hashmi</name></author><author><name sortKey="Ahmed, M" uniqKey="Ahmed M">M Ahmed</name></author><author><name sortKey="Murad, Mh" uniqKey="Murad M">MH Murad</name></author><author><name sortKey="Litzow, Mr" uniqKey="Litzow M">MR Litzow</name></author><author><name sortKey="Adams, Rh" uniqKey="Adams R">RH Adams</name></author><author><name sortKey="Ball, Lm" uniqKey="Ball L">LM Ball</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kamen, Dl" uniqKey="Kamen D">DL Kamen</name></author><author><name sortKey="Nietert, Pj" uniqKey="Nietert P">PJ Nietert</name></author><author><name sortKey="Wang, H" uniqKey="Wang H">H Wang</name></author><author><name sortKey="Duke, T" uniqKey="Duke T">T Duke</name></author><author><name sortKey="Cloud, C" uniqKey="Cloud C">C Cloud</name></author><author><name sortKey="Robinson, A" uniqKey="Robinson A">A Robinson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Rh" uniqKey="Lee R">RH Lee</name></author><author><name sortKey="Pulin, Aa" uniqKey="Pulin A">AA Pulin</name></author><author><name sortKey="Seo, Mj" uniqKey="Seo M">MJ Seo</name></author><author><name sortKey="Kota, Dj" uniqKey="Kota D">DJ Kota</name></author><author><name sortKey="Ylostalo, J" uniqKey="Ylostalo J">J Ylostalo</name></author><author><name sortKey="Larson, Bl" uniqKey="Larson B">BL Larson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shetty, Ak" uniqKey="Shetty A">AK Shetty</name></author><author><name sortKey="Upadhya, R" uniqKey="Upadhya R">R Upadhya</name></author><author><name sortKey="Madhu, Ln" uniqKey="Madhu L">LN Madhu</name></author><author><name sortKey="Kodali, M" uniqKey="Kodali M">M Kodali</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shetty, Ak" uniqKey="Shetty A">AK Shetty</name></author><author><name sortKey="Kodali, M" uniqKey="Kodali M">M Kodali</name></author><author><name sortKey="Upadhya, R" uniqKey="Upadhya R">R Upadhya</name></author><author><name sortKey="Madhu, Ln" uniqKey="Madhu L">LN Madhu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thomas, R" uniqKey="Thomas R">R Thomas</name></author><author><name sortKey="Wang, W" uniqKey="Wang W">W Wang</name></author><author><name sortKey="Su, Dm" uniqKey="Su D">DM Su</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oh, Sj" uniqKey="Oh S">SJ Oh</name></author><author><name sortKey="Lee, Jk" uniqKey="Lee J">JK Lee</name></author><author><name sortKey="Shin, Os" uniqKey="Shin O">OS Shin</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="editorial"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Aging Dis</journal-id><journal-id journal-id-type="iso-abbrev">Aging Dis</journal-id><journal-title-group><journal-title>Aging and Disease</journal-title></journal-title-group><issn pub-type="epub">2152-5250</issn><publisher><publisher-name>JKL International LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32257554</article-id><article-id pub-id-type="pmc">7069463</article-id><article-id pub-id-type="publisher-id">ad-11-2-462</article-id><article-id pub-id-type="doi">10.14336/AD.2020.0301</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shetty</surname><given-names>Ashok K</given-names></name><xref ref-type="corresp" rid="cor1-ad-11-2-462"><sup>*</sup></xref></contrib><aff id="aff16-ad-11-2-462"><addr-line>Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, Texas, USA</addr-line></aff></contrib-group><author-notes><corresp id="cor1-ad-11-2-462"><label>*</label>Correspondence should be addressed to: Dr. Ashok K. Shetty, Institute for Regenerative Medicine, Texas A&M Health Science Center, College of Medicine, College Station, TX 77843, USA. E-mail: <email>akskrs@tamu.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>4</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>9</day><month>3</month><year>2020</year></pub-date><volume>11</volume><issue>2</issue><fpage>462</fpage><lpage>464</lpage><history><date date-type="received"><day>1</day><month>3</month><year>2020</year></date><date date-type="rev-request"><day>1</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>1</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>Copyright: © 2020 Shetty et al.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.</license-p></license></permissions><abstract><p>A new study published by the journal Aging & Disease reported that intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with coronavirus disease 2019 (COVID-19) resulted in improved functional outcomes (<italic>Leng et al., Aging Dis, 11:216-228, 2020</italic>). This study demonstrated that intravenous infusion of MSCs is a safe and effective approach for treating patients with COVID-19 pneumonia, including elderly patients displaying severe pneumonia. COVID-19 is a severe acute respiratory illness caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, treating COVID-19 patients, particularly those afflicted with severe pneumonia, is challenging as no specific drugs or vaccines against SARS-CoV-2 are available. Therefore, MSC therapy inhibiting the overactivation of the immune system and promoting endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection found in this study is striking. Additional studies in a larger cohort of patients are needed to validate this therapeutic intervention further, however.</p></abstract></article-meta></front><body><p>A new study published by the journal “Aging & Disease” by a team led by Dr. Zhao reports that intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into seven patients with Coronavirus Disease 2019 (COVID-19) resulted in improved functional outcomes and facilitated recovery [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>]. COVID-19 is a severe acute respiratory illness caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [<xref rid="b2-ad-11-2-462" ref-type="bibr">2</xref>-<xref rid="b3-ad-11-2-462" ref-type="bibr">3</xref>]. This new corona-virus has elicited a pandemic of respiratory ailment since December 2019. It first appeared in Wuhan, China, but has now disseminated to multiple countries in the world, including the United States [<xref rid="b2-ad-11-2-462" ref-type="bibr">2</xref>-<xref rid="b3-ad-11-2-462" ref-type="bibr">3</xref>]. Even with painstaking global restraint and confinement efforts, the prevalence of COVID-19 continues to climb, with an increasing number of new cases and significant mortality worldwide [<xref rid="b3-ad-11-2-462" ref-type="bibr">3</xref>]. Coronaviruses are commonly found in people and multiple species of animals. Sometimes, animal coronaviruses infect people and spread from person to person [<xref rid="b4-ad-11-2-462" ref-type="bibr">4</xref>]. SARS-CoV-2, one such example, causes mild to severe symptoms, which include fever, cough, and shortness of breath, but severe cases (~2%) have been observed to result in death [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>-<xref rid="b3-ad-11-2-462" ref-type="bibr">3</xref>].</p><p>The pathogenesis of SARS-CoV-2 has been suggested to include the recognition of the angiotensin I converting enzyme 2 receptor (ACE2) by its spike protein, and priming of its spike protein by the cellular transmembrane protease, serine 2 (TMPRSS2) facilitating host cell entry and spread [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>,<xref rid="b5-ad-11-2-462" ref-type="bibr">5</xref>-<xref rid="b6-ad-11-2-462" ref-type="bibr">6</xref>]. Severe respiratory illness is a significant symptom of SARS-CoV-2 infection because the ACE2 receptor is widely expressed in the lung alveolar type II cells and capillary endothelial cells. Besides, alveolar cells express TMPRSS2 [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>,<xref rid="b7-ad-11-2-462" ref-type="bibr">7</xref>]. Infection of the lung by this virus leads to a cytokine storm with elevated levels of multiple proinflammatory cytokines, which causes edema, air exchange dysfunction, acute respiratory distress, secondary infection, which may result in death [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>]. ACE2 expression is also seen in other tissues such as the heart, liver, kidney, and digestive organs. Such expression pattern explains why infected ICU patients are afflicted with not only acute respiratory distress syndrome but also other complications such as myocardial injury, arrhythmia, acute kidney injury, shock, and death from multiple organ dysfunction syndromes [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>,<xref rid="b8-ad-11-2-462" ref-type="bibr">8</xref>]. The World Health Organization has proclaimed this epidemic as a global public health emergency [<xref rid="b3-ad-11-2-462" ref-type="bibr">3</xref>]. Currently, treating COVID-19 patients, particularly those afflicted with severe pneumonia, is challenging as no specific drugs or vaccines against SARS-CoV-2 are available [<xref rid="b9-ad-11-2-462" ref-type="bibr">9</xref>]. Therefore, identifying a safe and effective treatment for severely affected COVID-19 patients is critical for saving lives.</p><p>In the study by Dr. Zhao and collaborators, seven patients with COVID-19 pneumonia displayed improved functional outcomes and recovered after an intravenous administration of clinical-grade human MSCs [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>]. The chosen patients were positive for SARS-CoV-2, with one displaying critically severe type, 4 exhibiting severe types, and the other 2 showing common types of the syndrome. An additional three patients with severe types were enrolled for placebo control. Before MSC infusion, all patients displayed high fever, shortness of breath, low oxygen saturation, and pneumonia. The patients received 1 million MSCs per kilogram body weight when their symptoms were getting worse and were observed closely for 14 days. Notably, the study found that virtually all symptoms subsided by 2-4 days after receiving MSC infusion with no apparent adverse effects. Chest CT imaging demonstrated that chest pneumonia infiltration was significantly subsided. Also, the majority of patients showed negative results for the SARS-CoV-2 nucleic acid test over a week or two after MSC infusion. The overall improvement was quite extraordinary for an elderly patient in a critical condition after the infection [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>].</p><p>MSCs have been employed extensively in cell therapy, which includes a plethora of preclinical research investigations as well as a significant number of clinical trials [<xref rid="b10-ad-11-2-462" ref-type="bibr">10</xref>-<xref rid="b13-ad-11-2-462" ref-type="bibr">13</xref>]. Safety and efficacy have been shown in many clinical trials. The notable examples include the immune-mediated inflammatory diseases, such as graft-versus-host disease and systemic lupus erythematosus [<xref rid="b14-ad-11-2-462" ref-type="bibr">14</xref>-<xref rid="b15-ad-11-2-462" ref-type="bibr">15</xref>]. Improved function after MSC infusions in multiple disease conditions has been mostly attributed to immunomodulatory effects, as these cells secrete a variety of paracrine factors, which interact with immune cells resulting eventually in immunomodulation [<xref rid="b10-ad-11-2-462" ref-type="bibr">10</xref>-<xref rid="b13-ad-11-2-462" ref-type="bibr">13</xref>]. The mechanisms underlying the improvements after MSC infusion in COVID-19 patients also appeared to be the robust antiinflammatory activity of MSCs. Such processes were evident from multiple beneficial outcomes, which include an increased number of peripheral lymphocytes, the decline in the C-reactive protein, and waning of overactivated cytokine-secreting immune cells (CXCR3<sup>+</sup>CD4<sup>+</sup> T cells, CXCR3<sup>+</sup>CD8<sup>+</sup> T cells, and CXCR3<sup>+</sup> NK cells) by 3-6 days in the circulating blood [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>]. Moreover, a group of CD14<sup>+</sup>CD11c<sup>+</sup>CD11bmid regulatory dendritic cell (DC) population increased after MSC treatment. Also, in comparison to the placebo group, the patients receiving MSCs displayed a decreased level of tumor necrosis factor-alpha, a major pro-inflammatory cytokine, with concurrent elevation in the concentration of the antiinflammatory protein interleukin-10 [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>]. Furthermore, 10 x RNA-sequencing uncovered that infused MSCs were negative for ACE2 and TMPRSS2, which implied that MSCs were free from COVID-19 infection. Besides, multiple antiinflammatory and trophic factors were highly expressed in MSCs. Also, the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis suggested that MSCs were involved in antiviral pathways [<xref rid="b1-ad-11-2-462" ref-type="bibr">1</xref>].</p><p>Remarkably, the study by Dr. Zhao and colleagues showed that intravenous MSC infusion could reduce the overactivation of the immune system and support repair by modulating the lung microenvironment after SARS-CoV-2 infection even in elderly patients. Intravenous infusion of MSCs typically leads to their accumulation in the lungs, where they secrete multiple paracrine factors [<xref rid="b16-ad-11-2-462" ref-type="bibr">16</xref>]. Such factors likely played a significant role in protecting or rejuvenating alveolar epithelial cells, counteracting fibrosis, and improving lung function. MSC infusion would likely be particularly beneficial to elderly individuals infected with SARS-CoV-2, both with and without co-morbidities, as this population is more susceptible to SARS-CoV-2 induced pneumonia, resulting in severe respiratory distress and death because of immunosenescence [<xref rid="b17-ad-11-2-462" ref-type="bibr">17</xref>-<xref rid="b20-ad-11-2-462" ref-type="bibr">20</xref>]. In summary, this study showed that intravenous infusion of MSCs is a safe and efficient approach for treating patients with COVID-19 pneumonia, including in elderly patients displaying severe pneumonia. Additional studies in a larger cohort of patients are needed to validate this therapeutic intervention further, however.</p></body><back><ack><title>Acknowledgments</title><p>The author is supported by grants from the National Institute of Neurological Disorders and Stroke (1R01NS106907-01) and the Department of Defense (W81XWH-14-1-0572 and W81XWH-16-1-0480)</p></ack><ref-list><title>References</title><ref id="b1-ad-11-2-462"><label>[1]</label><mixed-citation publication-type="journal"><name><surname>Leng</surname><given-names>Z</given-names></name>, <name><surname>Zhu</surname><given-names>R</given-names></name>, <name><surname>Hou</surname><given-names>W</given-names></name>, <name><surname>Feng</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Han</surname><given-names>Q</given-names></name>, <etal>et al</etal> (<year>2020</year>). <article-title>Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia</article-title>. <source>Aging Dis</source>, <volume>11</volume>:<fpage>216</fpage>-<lpage>228</lpage>.</mixed-citation></ref><ref id="b2-ad-11-2-462"><label>[2]</label><mixed-citation publication-type="journal"><name><surname>Munster</surname><given-names>VJ</given-names></name>, <name><surname>Koopmans</surname><given-names>M</given-names></name>, <name><surname>van Doremalen</surname><given-names>N</given-names></name>, <name><surname>van Riel</surname><given-names>D</given-names></name>, <name><surname>de Wit</surname><given-names>E</given-names></name> (<year>2020</year>). <article-title>A novel coronavirus emerging in China - key questions for impact assessment</article-title>. <source>New England Journal of Medicine</source>, in press.</mixed-citation></ref><ref id="b3-ad-11-2-462"><label>[3]</label><mixed-citation publication-type="journal"><name><surname>Sohrabi</surname><given-names>C</given-names></name>, <name><surname>Alsafi</surname><given-names>Z</given-names></name>, <name><surname>O'Neill</surname><given-names>N</given-names></name>, <name><surname>Khan</surname><given-names>M</given-names></name>, <name><surname>Kerwan</surname><given-names>A</given-names></name>, <name><surname>Al-Jabir</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2020</year>). <article-title>World Health Organization declares Global Emergency: A review of the 2019 Novel Coronavirus (COVID-19)</article-title>. <source>Int J Surg</source>, pii: <volume>S1743-9191</volume>(<issue>20</issue>)<fpage>30197</fpage>-<lpage>7</lpage>.</mixed-citation></ref><ref id="b4-ad-11-2-462"><label>[4]</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>Q</given-names></name>, <name><surname>Guo</surname><given-names>D</given-names></name> (<year>2020</year>). <article-title>Emerging coronaviruses: Genome structure, replication, and pathogenesis</article-title>. <source>J Med Virol</source>, <volume>92</volume>(<issue>4</issue>):<fpage>418</fpage>-<lpage>423</lpage>.<pub-id pub-id-type="pmid">31967327</pub-id></mixed-citation></ref><ref id="b5-ad-11-2-462"><label>[5]</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>R</given-names></name>, <name><surname>Zhao</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Niu</surname><given-names>P</given-names></name>, <name><surname>Yang</surname><given-names>B</given-names></name>, <name><surname>Wu</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2020</year>). <article-title>Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title>. <source>Lancet</source>, <volume>395</volume>:<fpage>565</fpage>-<lpage>574</lpage><pub-id pub-id-type="pmid">32007145</pub-id></mixed-citation></ref><ref id="b6-ad-11-2-462"><label>[6]</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>P</given-names></name>, <name><surname>Yang</surname><given-names>X-L</given-names></name>, <name><surname>Wang</surname><given-names>X-G</given-names></name>, <name><surname>Hu</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2020</year>). <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source>, in press.</mixed-citation></ref><ref id="b7-ad-11-2-462"><label>[7]</label><mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>M</given-names></name>, <name><surname>Kleine-Weber</surname><given-names>H</given-names></name>, <name><surname>Krüger</surname><given-names>N</given-names></name>, <name><surname>Müller</surname><given-names>M</given-names></name>, <name><surname>Drosten</surname><given-names>C</given-names></name>, <name><surname>Pöhlmann</surname><given-names>S</given-names></name> (<year>2020</year>). <article-title>The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells</article-title>. <source>bioRxiv</source>:2020.2001.2031.929042.</mixed-citation></ref><ref id="b8-ad-11-2-462"><label>[8]</label><mixed-citation publication-type="journal"><name><surname>Hamming</surname><given-names>I</given-names></name>, <name><surname>Timens</surname><given-names>W</given-names></name>, <name><surname>Bulthuis</surname><given-names>MLC</given-names></name>, <name><surname>Lely</surname><given-names>AT</given-names></name>, <name><surname>Navis</surname><given-names>GJ</given-names></name>, <name><surname>van Goor</surname><given-names>H</given-names></name> (<year>2004</year>). <article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title>. <source>J Patho</source>, <volume>203</volume>:<fpage>631</fpage>-<lpage>637</lpage>.</mixed-citation></ref><ref id="b9-ad-11-2-462"><label>[9]</label><mixed-citation publication-type="journal"><name><surname>Fauci</surname><given-names>AS</given-names></name>, <name><surname>Lane</surname><given-names>HC</given-names></name>, <name><surname>Redfield</surname><given-names>RR</given-names></name> (<year>2020</year>). <article-title>Covid-19 - Navigating the uncharted</article-title>. <source>N Engl J Med</source>. <month>2</month><day>28</day>.</mixed-citation></ref><ref id="b10-ad-11-2-462"><label>[10]</label><mixed-citation publication-type="journal"><name><surname>Prockop</surname><given-names>DJ</given-names></name>, <name><surname>Oh</surname><given-names>JY</given-names></name> (<year>2012</year>). <article-title>Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation</article-title>. <source>Mol Ther</source>, <volume>20</volume>:<fpage>14</fpage>-<lpage>20</lpage>.<pub-id pub-id-type="pmid">22008910</pub-id></mixed-citation></ref><ref id="b11-ad-11-2-462"><label>[11]</label><mixed-citation publication-type="journal"><name><surname>Prockop</surname><given-names>DJ</given-names></name> (<year>2017</year>). <article-title>The exciting prospects of new therapies with mesenchymal stromal cells</article-title>. <source>Cytotherapy</source>, <volume>19</volume>:<fpage>1</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">27769637</pub-id></mixed-citation></ref><ref id="b12-ad-11-2-462"><label>[12]</label><mixed-citation publication-type="journal"><name><surname>Connick</surname><given-names>P</given-names></name>, <name><surname>Kolappan</surname><given-names>M</given-names></name>, <name><surname>Crawley</surname><given-names>C</given-names></name>, <name><surname>Webber</surname><given-names>DJ</given-names></name>, <name><surname>Patani</surname><given-names>R</given-names></name>, <name><surname>Michell</surname><given-names>AW</given-names></name>, <etal>et al</etal> (<year>2012</year>). <article-title>Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study</article-title>. <source>Lancet Neurology</source>, <volume>11</volume>:<fpage>150</fpage>-<lpage>156</lpage><pub-id pub-id-type="pmid">22236384</pub-id></mixed-citation></ref><ref id="b13-ad-11-2-462"><label>[13]</label><mixed-citation publication-type="journal"><name><surname>Wilson</surname><given-names>JG</given-names></name>, <name><surname>Liu</surname><given-names>KD</given-names></name>, <name><surname>Zhuo</surname><given-names>NJ</given-names></name>, <name><surname>Caballero</surname><given-names>L</given-names></name>, <name><surname>McMillan</surname><given-names>M</given-names></name>, <name><surname>Fang</surname><given-names>XH</given-names></name>, <etal>et al</etal> (<year>2015</year>). <article-title>Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial</article-title>. <source>Lancet Respiratory Medicine</source>, <volume>3</volume>:<fpage>24</fpage>-<lpage>32</lpage>.<pub-id pub-id-type="pmid">25529339</pub-id></mixed-citation></ref><ref id="b14-ad-11-2-462"><label>[14]</label><mixed-citation publication-type="journal"><name><surname>Hashmi</surname><given-names>S</given-names></name>, <name><surname>Ahmed</surname><given-names>M</given-names></name>, <name><surname>Murad</surname><given-names>MH</given-names></name>, <name><surname>Litzow</surname><given-names>MR</given-names></name>, <name><surname>Adams</surname><given-names>RH</given-names></name>, <name><surname>Ball</surname><given-names>LM</given-names></name>, <etal>et al</etal> (<year>2016</year>). <article-title>Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis</article-title>. <source>Lancet Haematology</source>, <volume>3</volume>:<fpage>E45</fpage>-<lpage>E52</lpage>.<pub-id pub-id-type="pmid">26765648</pub-id></mixed-citation></ref><ref id="b15-ad-11-2-462"><label>[15]</label><mixed-citation publication-type="journal"><name><surname>Kamen</surname><given-names>DL</given-names></name>, <name><surname>Nietert</surname><given-names>PJ</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Duke</surname><given-names>T</given-names></name>, <name><surname>Cloud</surname><given-names>C</given-names></name>, <name><surname>Robinson</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2018</year>). <article-title>CT-04 Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cells (MSCs) in patients with systemic lupus erythematosus: results of an open-label phase I study</article-title>. <source>Lupus Science & Medicine</source>, <volume>5</volume>:<fpage>A46</fpage>-<lpage>A47</lpage>.</mixed-citation></ref><ref id="b16-ad-11-2-462"><label>[16]</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>RH</given-names></name>, <name><surname>Pulin</surname><given-names>AA</given-names></name>, <name><surname>Seo</surname><given-names>MJ</given-names></name>, <name><surname>Kota</surname><given-names>DJ</given-names></name>, <name><surname>Ylostalo</surname><given-names>J</given-names></name>, <name><surname>Larson</surname><given-names>BL</given-names></name><etal>et al</etal> (<year>2009</year>). <article-title>Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6</article-title>. <source>Cell Stem Cell</source>, <volume>5</volume>:<fpage>54</fpage>-<lpage>63</lpage>.<pub-id pub-id-type="pmid">19570514</pub-id></mixed-citation></ref><ref id="b17-ad-11-2-462"><label>[17]</label><mixed-citation publication-type="journal"><name><surname>Shetty</surname><given-names>AK</given-names></name>, <name><surname>Upadhya</surname><given-names>R</given-names></name>, <name><surname>Madhu</surname><given-names>LN</given-names></name>, <name><surname>Kodali</surname><given-names>M</given-names></name> (<year>2019</year>). <article-title>Novel Insights on Systemic and Brain Aging, Stroke, Amyotrophic Lateral Sclerosis, and Alzheimer's Disease</article-title>. <source>Aging Dis</source>, <volume>10</volume>:<fpage>470</fpage>-<lpage>482</lpage>.<pub-id pub-id-type="pmid">31011489</pub-id></mixed-citation></ref><ref id="b18-ad-11-2-462"><label>[18]</label><mixed-citation publication-type="journal"><name><surname>Shetty</surname><given-names>AK</given-names></name>, <name><surname>Kodali</surname><given-names>M</given-names></name>, <name><surname>Upadhya</surname><given-names>R</given-names></name>, <name><surname>Madhu</surname><given-names>LN</given-names></name> (<year>2018</year>). <article-title>Emerging Anti-Aging Strategies - Scientific Basis and Efficacy</article-title>. <source>Aging Dis</source>, <volume>9</volume>:<fpage>1165</fpage>-<lpage>1184</lpage>.<pub-id pub-id-type="pmid">30574426</pub-id></mixed-citation></ref><ref id="b19-ad-11-2-462"><label>[19]</label><mixed-citation publication-type="journal"><name><surname>Thomas</surname><given-names>R</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Su</surname><given-names>DM</given-names></name> (<year>2020</year>). <article-title>Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging</article-title>. <source>Immun Ageing</source>, <volume>17</volume>:<fpage>2</fpage>.<pub-id pub-id-type="pmid">31988649</pub-id></mixed-citation></ref><ref id="b20-ad-11-2-462"><label>[20]</label><mixed-citation publication-type="journal"><name><surname>Oh</surname><given-names>SJ</given-names></name>, <name><surname>Lee</surname><given-names>JK</given-names></name>, <name><surname>Shin</surname><given-names>OS</given-names></name> (<year>2019</year>). <article-title>Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity</article-title>. <source>Immune Network</source>, <volume>19</volume>:<fpage>e37</fpage>.<pub-id pub-id-type="pmid">31921467</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000A19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7069463
|texte= Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:32257554" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |